Valeant hikes profits forecast, touts buyout strategies; Actavis raises sales expectations;

 @FiercePharma: Provigil generics drag Teva profits down; sales off 3.9%. Copaxone up 17%, but how long can that last w/ new MS competition? | Follow @FiercePharma

 @EricPFierce: Pharma cargo thefts spike as robbers hit pharmacy delivery van in "last-mile" attacks. Chances of violence higher. Article | Follow @EricPFierce

> Valeant Pharmaceuticals hiked its 2013 profits forecast and talked up plans for acquisitions in high-growth markets overlooked by Big Pharma. Report

> Actavis ($ACT) posted a first-quarter loss on acquisition charges, but encouraged by sales growth, raised its full-year earnings estimate by 40 cents per share. Report

> Shire ($SHPG) cut its forecast for 2013 sales as some of its drugs fell short of first-quarter expectations and profits depended on cost-cutting. Report

> The U.S. Justice Department appealed a federal judge's ruling requiring regulators to provide emergency contraception to women and girls of all ages; the appeal comes after FDA loosened age restrictions on the Plan B One-Step product. Report

> GlaxoSmithKline ($GSK) hired JP Morgan and Greenhill to advise it on the sale of its drinks brands Lucozade and Ribena, a deal expected to be worth more than $1.6 billion. Report

Medical Device News

 @FierceMedDev: FDA slaps Class I on Covidien's ventilator battery recall. News | Follow @FierceMedDev

 @MarkHFierce: Smith & Nephew nailed down some M&A in India and launched a $300M share buyback. The goal: renewed growth. Article | Follow @MarkHFierce

 @DamianFierce: St. Jude is studying its next-gen CRT-D with an eye on FDA approval. More | Follow @DamianFierce

> Cardiovascular Systems' Q3 revenue grows. Story

> Study: Zinc may be ideal for bioabsorbable stents. More

> Australian team advances Alzheimer's blood test work. DxExtra

Biotech News

 @FierceBiotech: Flemming Ornskov -The 25 most influential people in biopharma today. Profile | Follow @FierceBiotech

 @JohnCFierce: New Shire CEO Ornskov shakes up company after seizing the rein. Article | Follow @JohnCFierce

 @RyanMFierce: Gilead is trading up about 5% on Ph2 news of 95%-plus SVR rates with sofosbuvir + ledipasvir w/ & w/o ribavirin. One patient relapsed. | Follow @RyanMFierce

> Biotech Symphogen tacks on $53.7M to big venture round after Merck Serono deal. More

> Billionaire Kirk grabs $150M round for synthetic biology deals at Intrexon. News

> Merck buddies up to Scripps spinout Abide in $430M diabetes partnership. Article

> J&J grabs another 'breakthrough' FDA win with early-stage cancer drug. News

Pharma Manufacturing News

> China sets rules for excipient makers after scandal. News

> Manufacturing issues trip up approval for Gilead, Impax. Article

> Cargo thefts spike as robbers target pharmacy deliveries. Report

> More recalls as Hospira struggles to right manufacturing. Story

Vaccines News

> H7N9 may have evolved from four origins. Item

> GSK, Sanofi vaccines proving effective in measles outbreak. Report

> U.K. vaccine expansion a boon for GSK and Merck. More

> Merck's Gardasil looks effective in two-shot regimen. Article

> Search goes on for HIV vaccine after NIH trial nixed. Story

And Finally... New findings about the genetic characteristics of uterine cancer identified mutations that set apart patients with aggressive disease. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.